BrainStorm Cell Therapeutics NTF Cells Shows Significant Advantage In Pre-Clinical Study For Parkinson’s Disease

BrainStorm Cell Therapeutics Inc. (OTCBB:BCLI), a leading developer of adult stem cell technologies and therapeutics, announced that in a pre-clinical study that was conducted with Tel Aviv University between February and May 2008, signs of impaired motor behavior in a rat model of Parkinson’s improved following transplantation of BrainStorm’s unique Neurotrophic Factor Cells (NTF).

More: continued here

Filed under: Neurology / Neuroscience on June 1st, 2008